Divalproex sodium

Seizure Disorders

Divalproex sodium is an anticonvulsant used to treat several types of epilepsy. It may be prescribed alone or in combination with other medications for the following conditions:

• Complex partial seizures: These seizures may occur alone or in association with other types of seizures.
• Absence seizures: This includes both simple and complex absence seizures, which are characterized by brief lapses in consciousness.

Bipolar Disorder

This medication is used to treat the manic phase associated with bipolar disorder. These episodes often involve periods of abnormally high energy, racing thoughts, impulsivity, or irritability. Divalproex sodium helps stabilize mood during these periods.

Migraine Prevention

Divalproex sodium is used to reduce the frequency of migraine headaches. It is important to note that this medication is a preventive treatment and is not intended to treat a migraine headache that has already begun.

Mechanism of Action

Divalproex sodium is an anticonvulsant medication that works within the central nervous system. While the exact way it works is not completely understood, it is believed to increase the levels of a specific chemical messenger in the brain called gamma-aminobutyric acid (GABA).

The Role of GABA

GABA is an inhibitory neurotransmitter, which means it helps block or inhibit certain brain signals and decreases activity in the nervous system. By increasing GABA levels, divalproex sodium helps to:

• Reduce Seizure Activity: It calms the excessive electrical activity in the brain that leads to seizures.
• Stabilize Mood: It helps manage the overactive nerve signals associated with manic episodes in bipolar disorder.
• Prevent Migraines: It may reduce the brain's sensitivity to triggers that cause migraine headaches.

Divalproex sodium is a compound made of sodium valproate and valproic acid. Once it enters the body, it is converted into valproate, which is the active component that interacts with brain cells to produce these effects.

Common Side Effects

Many people experience mild side effects when starting divalproex sodium. These may include:

• Nausea, vomiting, or stomach pain
• Diarrhea or constipation
• Drowsiness, dizziness, or weakness
• Tremors or shaking
• Weight gain or changes in appetite
• Temporary hair loss
• Blurred or double vision

Serious Side Effects

Some side effects require immediate medical attention. Contact a healthcare provider right away if you notice:

• Signs of liver problems, such as yellowing of the skin or eyes, dark urine, or pain on the right side of the stomach
• Severe pain in the upper stomach spreading to the back, which may indicate pancreatitis
• New or worsening depression, anxiety, or suicidal thoughts
• Unusual bruising or bleeding
• Increased confusion, extreme tiredness, or a significant drop in body temperature
• A severe skin rash, fever, or swollen glands

Boxed Warnings

Divalproex sodium includes boxed warnings for several life-threatening conditions:

• Liver Failure: Severe or fatal liver damage has occurred, most often during the first six months of use. The risk is highest for children under two years old and those with certain metabolic conditions.
• Birth Defects: Exposure during pregnancy can cause major birth defects, such as spina bifida, and may result in lower IQ or developmental delays in the child. It is generally avoided for migraine prevention in pregnant individuals.
• Pancreatitis: Cases of life-threatening inflammation of the pancreas have been reported. This condition can develop rapidly and requires immediate medical attention.

Suicidal Thoughts and Behavior

Antiepileptic medications, including divalproex sodium, may increase the risk of suicidal thoughts or actions. Monitoring for new or worsening depression, anxiety, or unusual changes in mood is important.

Urea Cycle Disorders

This medication is contraindicated in people with urea cycle disorders. Use in these individuals can lead to dangerous levels of ammonia in the blood, which can be fatal.

Mitochondrial Disorders

Patients with hereditary mitochondrial diseases, such as those caused by mutations in the POLG gene, have a significantly higher risk of drug-induced liver failure.

Blood Disorders

Divalproex sodium can lower the number of platelets in the blood, which may lead to easy bruising or bleeding. Healthcare providers typically monitor blood counts during treatment.

Serious Skin Reactions

Serious multi-organ hypersensitivity reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. These require immediate medical evaluation as they can be fatal.

Pregnancy Risks

Divalproex sodium carries a boxed warning regarding its use during pregnancy due to the risk of significant harm to the developing fetus. Exposure to this medication in the womb can cause major birth defects, including neural tube defects such as spina bifida. These defects often occur very early in pregnancy, sometimes before a person is aware they are pregnant.

Research indicates that children exposed to divalproex sodium during pregnancy may also face long-term developmental challenges, including:

• Lower IQ scores compared to children exposed to other anti-seizure medications.
• Increased risk of autism spectrum disorders.
• Developmental delays in speech and motor skills.
• Higher rates of attention deficit hyperactivity disorder (ADHD).

Usage Guidelines

For the prevention of migraine headaches, divalproex sodium is generally contraindicated in pregnant individuals. For those treating epilepsy or bipolar disorder, healthcare providers typically only recommend this medication if other treatments have failed to provide adequate control. People of childbearing age are usually advised to use effective contraception while taking this medication and to discuss pregnancy planning with a healthcare professional.

Breastfeeding

Divalproex sodium is excreted into breast milk. While it is often used by breastfeeding individuals, healthcare providers generally recommend close monitoring of the nursing infant. Potential concerns for the infant include signs of liver toxicity, such as jaundice (yellowing of the skin or eyes), or unusual bruising and bleeding. Decisions regarding breastfeeding while taking this medication involve weighing the benefits of breastfeeding against the potential risks to the infant.

Available Forms

Divalproex sodium is provided in the following oral formulations:

• Delayed-release tablets: These tablets are specially coated to release the medication after passing through the stomach to help minimize side effects like stomach upset.
• Extended-release tablets: These tablets release the medication slowly over a longer period of time.
• Delayed-release sprinkle capsules: These capsules contain coated pellets that can be swallowed whole or opened and sprinkled onto soft food for patients who have trouble swallowing tablets.

It is important to note that different forms of divalproex sodium may be absorbed differently by the body and are not always interchangeable without a healthcare provider's guidance.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved divalproex sodium for the following uses:

• Epilepsy: Treatment of complex partial seizures and simple or complex absence seizures.
• Bipolar Disorder: Treatment of manic episodes associated with bipolar disorder.
• Migraine: Prevention of migraine headaches (prophylaxis).

Boxed Warnings

Divalproex sodium carries several boxed warnings, which are the FDA's most serious warnings for medications:

• Hepatotoxicity: Serious or fatal liver failure has occurred, usually within the first six months of treatment. Children under two years of age and patients with mitochondrial disorders are at the highest risk.
• Teratogenicity: This medication can cause major birth defects, such as neural tube defects. It is also linked to decreased IQ and developmental delays in children exposed during pregnancy.
• Pancreatitis: Life-threatening cases of pancreatitis have been reported shortly after starting the medication or after years of use.

Regulatory Safety Communications

The FDA has issued multiple safety alerts regarding the use of valproate products, including divalproex sodium, during pregnancy. Due to the risk of decreased IQ and other developmental issues, the FDA has contraindicated its use for migraine prevention in pregnant women. For epilepsy or bipolar disorder, it should only be used in pregnant women if other treatments are ineffective or unacceptable.

Risks of Abrupt Discontinuation

It is essential to never stop taking divalproex sodium without medical supervision. Abruptly ending treatment can cause the condition being treated to worsen significantly.

Seizure Complications

For patients with epilepsy, stopping divalproex sodium suddenly can trigger status epilepticus. This is a medical emergency where seizures do not stop or occur so frequently that the person does not regain consciousness between them. Even if you do not experience status epilepticus, your seizures may return more frequently or with greater intensity.

Mood and Behavioral Changes

When used for bipolar disorder, stopping the medication quickly can lead to a rapid return of manic or depressive episodes. Patients may also experience increased irritability, anxiety, or other mood fluctuations during the withdrawal period.

The Tapering Process

To safely stop taking divalproex sodium, healthcare providers usually implement a gradual tapering schedule. This involves slowly reducing the dose over a period of time to allow the brain and body to adjust. Always follow your doctor's specific instructions for lowering your dose to minimize the risk of withdrawal symptoms.